Several other research firms have also recently weighed in on PCRX. Jefferies Group lowered their price objective on shares of Pacira Pharmaceuticals to $52.00 and set a buy rating on the stock in a research report on Thursday, November 9th. ValuEngine upgraded shares of Pacira Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, January 10th. Canaccord Genuity set a $42.00 price objective on shares of Pacira Pharmaceuticals and gave the company a hold rating in a research report on Wednesday, November 29th. Wedbush restated an outperform rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, October 25th. Finally, HC Wainwright set a $55.00 price objective on shares of Pacira Pharmaceuticals and gave the company a buy rating in a research report on Thursday, January 4th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $46.53.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded up $0.20 during trading on Tuesday, hitting $36.10. 645,500 shares of the stock traded hands, compared to its average volume of 1,013,697. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. The stock has a market cap of $1,464.58, a PE ratio of -27.56 and a beta of 1.88. Pacira Pharmaceuticals has a 12-month low of $29.40 and a 12-month high of $58.95.
In other Pacira Pharmaceuticals news, CEO David M. Stack sold 28,885 shares of the firm’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total value of $1,160,888.15. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP James B. Jones sold 850 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $41.11, for a total transaction of $34,943.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,075 shares of company stock worth $1,210,690. 6.60% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the business. Northern Trust Corp grew its holdings in Pacira Pharmaceuticals by 9.1% in the 2nd quarter. Northern Trust Corp now owns 505,529 shares of the company’s stock worth $24,114,000 after acquiring an additional 42,289 shares during the last quarter. State Street Corp grew its holdings in Pacira Pharmaceuticals by 1.0% in the 2nd quarter. State Street Corp now owns 1,118,083 shares of the company’s stock worth $53,340,000 after acquiring an additional 10,727 shares during the last quarter. Rice Hall James & Associates LLC grew its holdings in Pacira Pharmaceuticals by 18.4% in the 4th quarter. Rice Hall James & Associates LLC now owns 323,769 shares of the company’s stock worth $14,780,000 after acquiring an additional 50,335 shares during the last quarter. Epoch Investment Partners Inc. grew its holdings in Pacira Pharmaceuticals by 195.7% in the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after acquiring an additional 354,728 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its holdings in Pacira Pharmaceuticals by 26.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 111,193 shares of the company’s stock worth $5,304,000 after acquiring an additional 22,949 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: “Piper Jaffray Companies Reiterates $49.00 Price Target for Pacira Pharmaceuticals (PCRX)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2018/02/16/piper-jaffray-companies-reiterates-49-00-price-target-for-pacira-pharmaceuticals-pcrx.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.